Strategies for targeting the androgen receptor axis in prostate cancer-Reference-Cited by-同舟云学术

Strategies for targeting the androgen receptor axis in prostate cancer

Published:2014-09 Issue:9 Volume:19 Page:1493-1497
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Carver Brett S.

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference34 articles.

1. Studies on prostate cancer. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins;Cancer Res.,1941

2. Outcome predictions for patients with metastatic prostate cancer;Smaletz;Semin. Urol. Oncol.,2002

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N. Engl. J. Med.,2004

4. Biclutamide for advanced prostate cancer: the natural versus treated history of disease;Scher;J. Clin. Oncol.,1997

5. Flutamide versus predisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group;Fossa;J. Clin. Oncol.,2001

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL;Journal of Experimental & Clinical Cancer Research;2024-01-29

2. Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer;Pharmaceuticals;2023-05-12

3. Theranostics in Prostate Cancer;Molecular Imaging and Targeted Therapy;2023

4. Deregulated transcription factors and poor clinical outcomes in cancer patients;Seminars in Cancer Biology;2022-11

5. Synthesis of Hydantoin Androgen Receptor Antagonists and Study on Their Antagonistic Activity;Molecules;2022-09-10